Tokyo (JCN) Jan 10, 2006 - Kyowa Hakko Kogyo announced on January 10 that it has signed a licensing agreement with US pharmaceutical company Eli Lilly on mitotic kinesin Eg5 inhibitor, Kyowa Hakko’s proprietary compound for anti-tumor agents. Under the agreement terms, Eli Lilly will exclusively develop and market mitotic kinesin Eg5 worldwide except in Japan. Accordingly, Kyowa Hakko Kogyo receives an upfront payment, milestone payments and royalties on sales of commercialized products from Eli Lilly.
